TY - JOUR T1 - Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal JO - PharmacoEconomics UR - http://eprints.whiterose.ac.uk/108863/ PY - 2017/01/01 AU - Tappenden P AU - Harnan S AU - Ren S AU - Thokala P AU - Wong R AU - Mukuria C AU - Green C AU - Pledge S AU - Tidy J ED - DO - DOI: 10.1007/s40273-016-0440-x VL - 35 IS - 1 SP - 97 EP - 109 Y2 - 2025/04/15 ER -